Company NEOVACS

Equities

ALNEV

FR001400MV37

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 13:26:39 23/05/2024 BST			5-day change	1st Jan Change
0.1879 ^EUR	+4.33%		-5.10%	-90.60%

04-30

Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Number of employees: 23

EUR in Million	2022	Weight	2023	Weight	Delta
Immunotherapy 100.0 %	0	100.0 %	1	100.0 %	+47,868.71%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	0	100.0 %	1	100.0 %	+47,868.71%

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	140	0 ( 0.1248 %)	0	0.1248 %

Name	Equities	%	Valuation
Dominique Catteaux Gestion 0.000000 %	0	0.000000 %	- €
Allianz Global Investors GmbH (France) 0.000000 %	0	0.000000 %	- €
La Mondiale SAM (Investment Portfolio) 0.000000 %	0	0.000000 %	- €
Martin Maurel Gestion Institutionnelle SA 0.000000 %	0	0.000000 %	- €
Uzes Gestion SA 0.000000 %	0	0.000000 %	- €
La Financière Desselligny SA 0.000000 %	0	0.000000 %	- €
Cogéfi Gestion SA 0.000000 %	0	0.000000 %	- €

Neovacs SA

3-5, Impasse Reille

75014, Paris

http://www.neovacs.fr

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEOVACS	-90.60%	68.63K
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.55%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B

Other Biotechnology & Medical Research